Patent ID: 8236323

Claim:
A method to reduce inflammation directly in a human, canine, ursine, bovine or ovine subject, comprising identifying a subject that exhibits inflammation due to a localized immune response not resulting from infection, administering to said subject an amount of T4 immune stimulating factor (TISF) effective to reduce the inflammation in a time period shorter than that required for an adaptive immune response, wherein said TISF is an isolated thymus-derived cationic protein factor expressed by a cloned type II thymic epithelial cell line of human, bovine, canine or feline origin, having a molecular weight of about 50,000 Daltons on a polyacrylamide gel, an isoelectric point of about 6.5, and capable of inducing or enhancing cell-mediated immune responsiveness of mature T-cells and stimulating IL-2 production in a mammal.